In the quest to match its predecessor Soliris, Alexion's Ultomiris just notched a win in the autoimmune disorder myasthenia gravis. Alexion is trumpeting data showing Ultomiris met its primary ...
AstraZeneca is making new progress with its Ultomiris expansion plan. On the heels of an FDA approval, the C5 inhibitor has returned with a clinical win in a rare autoimmune disease affecting the ...
Novartis has its eye on the market held by a pair of AstraZeneca's rare disease gems. The latest data showing that the Swiss drugmakers' iptacopan increases hemoglobin levels in a disease called ...
Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of Complement C5 Inhibitors & C5 Receptor Antagonists" report has been added to ResearchAndMarkets.com's offering. This competitive intelligence ...
New, long-term data for VOYDEYA™ as add-on to ULTOMIRIS® or SOLIRIS® will show low rate of breakthrough hemolysis events and sustained improvements in quality-of-life measures in PNH with ...
Bart Scott, MD, Professor, Division of Hematology and Oncology at the University of Washington Medical Center, and Professor, Clinical Research Division at Fred Hutchinson Cancer Center, said: “The ...
Ultomiris (ravulizumab-cwvz) is a brand-name drug prescribed for certain autoimmune conditions. Ultomiris is given as an intravenous (IV) infusion by a healthcare professional. The drug’s dosing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results